Viral Vector Scientist
Neion Bio
Viral Vector Scientist
Neion Bio
Egg-based biopharmaceutical manufacturing platform
Neion Bio · New York, United States · Full-time · Posted 2026-09-14
Salary: USD 120,000–150,000
Workplace: on_site
Neion Bio is harnessing nature’s best molecular factory, the chicken egg, to make medicine affordable, accessible, and resilient. Using cutting edge genetic engineering and stem cell technology, we create “living bioreactors”, which act as fully autonomous 3D biomolecular printers, operating on existing industrial-scale infrastructure. Our platform can rapidly and scalably produce almost any protein, provide national resilience to drug shortages and de-risk complex supply chains, and ultimately take advantage of novel biological environments to solve unmet medical needs. We are on a mission to reimagine the way in which complex biological molecules are produced to transform human health.
At Neion Bio you will play a pivotal role in an early-stage, fast-growing company, working alongside leading scientists and entrepreneurs. You will have the opportunity to participate in the enormous potential upside while having a huge impact on the world.
We are looking for a talented virologist or molecular biologist on the scientist level experienced with the engineering, production and purification of viral vectors, including lentivirus, adenovirus and AAV; and with a deep understanding of the underlying receptor biology of viral vector transduction of cells, ideally in non-model organisms. This is a hands-on role.
Key Responsibilities:
Preferred qualifications:
Compensation: base salary is expected to be $120-150K depending on experience, with additional bonus compensation, equity compensation, and benefits including health insurance, dental insurance, vision insurance, and 401(k).
Powered by Workable
Neion Bio develops the Raptor platform, which uses genetic engineering to turn chicken eggs into living bioreactors that produce recombinant biologics such as monoclonal antibodies. By re-engineering eggs and growing avian germ cells, the company can manufacture therapeutic proteins inside eggs, aiming to lower capital costs and reduce the carbon footprint compared to traditional cell-culture methods. The business model centers on partnerships with pharmaceutical companies, offering co-development and supply agreements that provide upfront and milestone payments plus future profit sharing when products reach the market. Neion Bio differentiates itself from competitors by using egg-based bioreactors and precision genome engineering to enable cost-effective, localized production with a potentially simpler supply chain. The company’s goal is to transform biologic manufacturing by delivering affordable, scalable bioproduction for a wide range of biologic medicines and related molecules.
Explore more opportunities at Neion Bio